177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Oncotarget

Volumn 8, Issue 39, 2017, Pages 66112-66116

  von Eyben, Finn E ^a   Kiljunen, Timo ^b   Joensuu, Timo ^b   Kairemo, Kalevi ^b   Uprimny, Christian ^c   Virgolini, Irene ^c  

^a Center of Tobacco Control Research   (Denmark)

^b Docrates Oncology Clinic   (Finland)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Abiraterone; Cross over study; External beam radiotherapy; Lutetium radiolabled prostate membrane specfic antigen radioligand therapy; Metastatic prostate cancer

Indexed keywords

ABIRATERONE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHOLINE C 11; DEXAMETHASONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; UNCLASSIFIED DRUG;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; RADIOISOTOPE THERAPY; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 85030129412     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.19805     Document Type: Article

References (12)

1. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M 3rd. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. 2017.
2. Ervandian M, Hoyer M, Petersen SE, Sengelov L, Hansen S, Holmberg M, Sveistrup J, Meidahl Petersen P, Borre M. Salvage radiation therapy following radical prostatectomy. A national Danish study. Acta Oncol. 2016; 55:598-603.
3. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostatespecific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016; 70:926-37.
4. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017; 64:52-60.
5. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017; 44:1014-24.
6. Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. [Article in German]. Nuklearmedizin. 2016; 55:123-8.
7. von Eyben FE, Kangasmaki A, Kiljunen T, Joensuu T. Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: a case report. Tumori. 2013; 99:e120-3.
8. Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging. 2017; 44:788-800.
9. Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Katja H, Christiansen H, Derlin T. 68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. Anticancer Res. 2017; 37:1273-9.
10. Porres D, Pfister D, Thissen A, Kuru TH, Zugor V, Buettner R, Knuechel R, Verburg FA,5, Heidenreich A. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis. 2017; 20:85-92.
11. Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 2016.
12. Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H, Derlin T. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol. 2016; 192:431-9.